Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone DeficiencyGlobeNewsWire • 06/26/20
Ascendis Pharma A/S Announces Presentation of Preclinical Data for TransCon IL-2 β/γ at AACR Virtual Annual Meeting 2020GlobeNewsWire • 06/22/20
Ascendis Pharma Clears Technical Benchmark, Hitting 80-Plus RS RatingInvestors Business Daily • 06/10/20
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/20/20
Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial OfficerGlobeNewsWire • 05/11/20
Ascendis Pharma A/S Announces Top-line Data from Fixed Dose Portion of Phase 2 Trial Demonstrating Potential of TransCon™ PTH as a Replacement Therapy for HypoparathyroidismGlobeNewsWire • 04/19/20
Ascendis Pharma A/S Receives Orphan Drug Designation for TransCon™ hGH as Treatment for Growth Hormone Deficiency in the United StatesGlobeNewsWire • 04/15/20
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 04/02/20
Ascendis Pharma (ASND): Strong Industry, Solid Earnings Estimate RevisionsZacks Investment Research • 03/20/20
Ascendis Pharma A/S (ASND) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 03/17/20
Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/13/20
Ascendis Pharma: Technology To Remove Stringency Of Dosage Regimen At Heart Of SuccessSeeking Alpha • 12/10/19
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/19/19
Ascendis Pharma Expands TransCon™ PTH Phase 2 PaTH Forward Clinical Trial to Expedite Enrollment of Subjects Previously Treated with NATPARA® in the United StatesGlobeNewsWire • 11/14/19
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019GlobeNewsWire • 11/06/19
Ascendis Pharma A/S Receives Orphan Designation for TransCon™ hGH for the Treatment of Pediatric Growth Hormone Deficiency in EuropeGlobeNewsWire • 10/21/19